PT Indofarma Tbk (IDX: INAF)
Health Care · Pharmaceuticals · ID
Rp—
— today · — 1Y
PT Indofarma Tbk (IDX: INAF) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $23.91M and employs 788 people.
trading between 126.00 and 725.00.
Tweenvest scores PT Indofarma Tbk across four factors: quality 34/100, growth 0/100. Its strongest factor is quality.
INAF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.91M
- Revenue (TTM)
- $9.14M
- P/E
- —
- EPS
- -21.80
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- Rp725.00
- 52-week low
- Rp126.00
- Avg volume (3M)
- —
- Shares outstanding
- 3.10B
- Employees
- 788
- Next earnings
- —
About PT Indofarma Tbk
PT Indofarma Tbk, along with its affiliated entities, is dedicated to the production and marketing of pharmaceutical goods across Indonesia. The company's activities encompass the commerce and supply of a diverse range of items, including medications, medical equipment, healthcare provisions, various extracts, and herbal products. It also operates its own laboratory facilities and provides specific COVID-19 diagnostic services, such as rapid antigen testing, reverse transcription polymerase chain reaction (RT-PCR), and Genose tests. Additionally, the firm engages in the export of its merchandise. Established in 1918, Indofarma Tbk maintains its primary operations in Bekasi, Indonesia. Historically, the company was known as PT Indofarma (Persero) Tbk and now functions as a subsidiary of PT. Bio Farma.
- ISIN
- ID1000068406
- Founded
- 1918
- Listed since
- Apr 18, 2001
- Exchange
- Indonesia Stock Exchange
- Currency
- IDR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.70 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.02 | -0.74% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.20 | +0.36% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.